Targeting c-Jun and JunB proteins as potential anticancer cell therapy

Oncogene

Volumn 27, Issue 5, 2008, Pages 641-652

  Gurzov, E N ^a   Bakiri, L ^b   Alfaro, J M ^a   Wagner, E F ^b   Izquierdo, M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

B16 F10 cancer cells; c Jun; JunB; RNA interference; SP600125

Indexed keywords

1,5 ISOQUINOLINEDIOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN C JUN; PROTEIN P53; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; FIBROBLAST; FUNCTIONAL PROTEOMICS; GENE EXPRESSION SYSTEM; INOCULATION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RETROVIRUS;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; FIBROBLASTS; HUMANS; MELANOMA; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-JUN; RETROVIRIDAE; RNA INTERFERENCE; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

MURINAE; MUS;

EID: 38549145828     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210690     Document Type: Article

References (41)

1. Artus C, Maquarre E, Moubarak RS, Delettre C, Jasmin C, Susin SA et al. (2006). CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathway in human erythroleukemia cells. Oncogene 25: 5741-5751.
2. Bain J, McLauchlan H, Elliott M, Cohen P. (2003). The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204.
3. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681-13686.
4. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R. (1987). Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238: 1386-1392.
5. Bowden GT, Schneider B, Domann R, Kulesz-Martin M. (1994). Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis. Cancer Res 54: 1882s-1885s.
6. Brummelkamp TR, Bernards R, Agami R. (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247.
7. Chiu R, Angel P, Karin M. (1989). Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell 59: 979-986.
8. Choi BY, Choi HS, Ko K, Cho YY, Zhu F, Kang BS et al. (2005). The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat Struct Mol Biol 12: 699-707.
9. Curran T, Peters G, Van Beveren C, Teich NM, Verma IM. (1982). FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol 44: 674-682.
10. Curran T, Teich NM. (1982). Candidate product of the FBJ murine osteosarcoma virus oncogene: characterization of a 55,000-dalton phosphoprotein. J Virol 42: 114-122.
11. Deng T, Karin M. (1993). JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev 7: 479-490.
12. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M et al. (2003). Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112: 181-192.
13. Eferl R, Wagner EF. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
14. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M et al. (2005). Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther 313: 325-332.
15. Galluzzi L, Larochette N, Zamzami N, Kroemer G. (2006). Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25: 4812-4830.
16. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. (2005). c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391.
17. Gurzov EN, Izquierdo M. (2006). RNA interference against Hec1 inhibits tumor growth in vivo. Gene Therapy 13: 1-7.
18. Joseloff E, Bowden GT. (1997). Regulation of the transcription factor AP-1 in benign and malignant mouse keratinocyte cells. Mol Carcinog 18: 26-36.
19. Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM et al. (2004). Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64: 8960-8967.
20. Libermann TA, Zerbini LF. (2006). Targeting transcription factors for cancer gene therapy. Curr Gene Ther 6: 17-33.
21. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11: 447-460.
22. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. (2003). Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 101: 1513-1519.
23. Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA et al. (1996). Mitochondrial permeability transition triggers lymphocyte apoptosis. J Immunol 157: 4830-4836.
24. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O et al. (2007). JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 11: 361-374.
25. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. (2004). Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23: 596-604.
26. Nateri AS, Spencer-Dene B, Behrens A. (2005). Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437: 281-285.
27. Passegue B, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wargger EF. (2001). Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell 104: 21-32.
28. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. (2002). JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet 30: 158-166.
29. Passegue E, Wagner EF, Weissman IL. (2004). JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119: 431-443.
30. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX et al. (2005). JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 18: 1365-1370.
31. Rauscher III FJ, Sambucetti LC, Curran T, Distel RJ, Spiegelman BM. (1988). Common DNA binding site for Fos protein complexes and transcription factor AP-1. Cell 52: 471-480.
32. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J et al. (1999). Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13: 607-619.
33. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446.
34. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, Artwohl M et al. (2003). JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 102: 4159-4165.
35. Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ. (2006). c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37: 668-674.
36. Vogt PK. (2002). Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2: 465-469.
37. Xia HH, He H, Wang JD, Gu Q, Lin MC, Zou B et al. (2006). Induction of apoptosis and cell cycle arrest by a specific c-Jun NH(2)-terminal kinase (JNK) inhibitor, SP-600125, in gastrointestinal cancers. Cancer Lett 241: 268-274.
38. Yang MY, Liu TC, Chang JG, Lin PM, Lin SF. (2003). JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101: 3205-3211.
39. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ et al. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297: 259-263.
40. Zenz R, Wagner EF. (2006). Jun signalling in the epidermis: from developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol 38: 1043-1049.
41. Zhang W, Hart J, McLeod HL, Wang HL. (2005). Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol 124: 11-19.